Day Three Labs Acquires Revolutionary Pharmaceutical-Grade Cannabinoid Infusion Technology
DENVER, Jan. 11, 2022 /PRNewswire/ — Day Three Labs (DTL), a cannabinoid CPG ingredient manufacturer specializing in the development and commercialization of novel cannabis product solutions, has acquired a patented pharmaceutical-grade cannabinoid infusion technology developed by a leading Israeli bioscience company. The deal was led and structured by KEY Investment Partners with participation from Phyto Partners.
This first-of-its-kind technology allows ingested cannabinoids to naturally bypass patients’ and consumers’ first-pass metabolism, delivering significantly elevated levels of Delta 9-THC into the bloodstream without converting to 11-hydroxy-THC. As a result, DTL’s technology is able to consistently mimic the experience of smoking whole flower by taking effect within 10 minutes, enhancing bioavailability by upwards of 500% and capturing the plant’s entire cannabinoid and terpene profile.
DISCLAIMERS: This site is not intended to provide any investment, financial, legal, regulatory, accounting, tax or similar advice, and nothing on this site should be construed as a recommendation by Key Investment Partners LLC, its affiliates, or any third party, to acquire or dispose of any investment or security, or to engage in any investment strategy or transaction. An investment in any strategy involves a high degree of risk and there is always the possibility of loss, including the loss of principal. Nothing in this site may be considered as an offer or solicitation to purchase or sell securities or other services.
Leave a Reply
Want to join the discussion?Feel free to contribute!